Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2013
12/17/2013CA2553254C Long-term delivery formulations and methods of use thereof
12/17/2013CA2543045C Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
12/17/2013CA2530963C Phototherapy compositions and methods
12/17/2013CA2527583C Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
12/17/2013CA2504401C Drug delivery systems for the prevention of neointimal hyperlasia
12/17/2013CA2500577C The use of cytokine able to bind il-18bp and of inhibiting the activity of a second cytokine
12/17/2013CA2478997C Use of copper chelating tetraamines for the treatment of cardiovascular disease and heart failure
12/17/2013CA2478855C Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
12/17/2013CA2427310C Imaging, diagnosis and treatment of angiogenesis-related diseases comprising ecsm4
12/15/2013CA2820236A1 Non-viral nanoparticle-based delivery system
12/14/2013CA2779838A1 Treatment of cytokine mediated conditions
12/12/2013WO2013185124A1 Antimicrobial compounds, compositions and methods of use thereof
12/12/2013WO2013185112A1 Pharmaceuticl compositions for the treatment of cftr -mediated disorders
12/12/2013WO2013185108A1 Methods and products related to lung cancer
12/12/2013WO2013185105A1 Methods for treating neutropenia using retinoid agonists
12/12/2013WO2013185103A1 Macrocyclic inhibitors of flaviviridae viruses
12/12/2013WO2013185093A1 Macrocyclic inhibitors of flaviviridae viruses
12/12/2013WO2013185084A1 Pyrimidinyl tyrosine kinase inhibitors
12/12/2013WO2013185082A2 Inhibitors of bruton's tyrosine kinase
12/12/2013WO2013185055A1 Methods and compositions for the inhibition of pin1
12/12/2013WO2013185048A2 Heterocyclic guanidine f1f0-atpase inhibitors and therapeutic uses thereof
12/12/2013WO2013185046A1 Saturated acyl guanid1ne for inhibition of f1f0-atpase
12/12/2013WO2013185045A1 Indazole guanidine f1f0-atpase inhibitors and therapeutic uses thereof
12/12/2013WO2013185024A1 Treating burn and scar injury using tocotrienol
12/12/2013WO2013185022A1 Methods and compositions for improving pial collateral circulation and treating blood clotting disorders
12/12/2013WO2013184985A1 Inhibitors of influenza viruses replication
12/12/2013WO2013184934A1 Neprilysin inhibitors
12/12/2013WO2013184902A1 Chemical transformations of (-)-codeine to afford derivatives of codeine and morphine thereof
12/12/2013WO2013184898A1 Neprilysin inhibitors
12/12/2013WO2013184892A1 Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
12/12/2013WO2013184884A1 Improved methods for botanical and/or algae extraction
12/12/2013WO2013184878A1 Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
12/12/2013WO2013184876A1 Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
12/12/2013WO2013184845A1 Cyclic boronic acid ester derivatives and therapeutic uses thereof
12/12/2013WO2013184837A1 Methods of treating overweight and obesity
12/12/2013WO2013184830A1 5-ala for detection of brain tumors
12/12/2013WO2013184806A1 Inhibitors of respiratory syncytial virus
12/12/2013WO2013184780A1 Novel iminosugars and their applications
12/12/2013WO2013184766A1 Compounds and compositions for modulating egfr activity
12/12/2013WO2013184757A1 Compounds and compositions for modulating egfr activity
12/12/2013WO2013184734A1 Macrocyclic factor viia inhibitors
12/12/2013WO2013184732A1 Crystalline (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]4-penten-2-amine 1,5-naphthalenedisulfonate
12/12/2013WO2013184708A1 Pharmaceutical composition for treating inflammation and pain
12/12/2013WO2013184703A1 Pharmaceutical composition for treating inflammation and pain
12/12/2013WO2013184698A1 Solid forms of an antiviral compound
12/12/2013WO2013184681A1 Crystalline forms of an androgen receptor modulator
12/12/2013WO2013184650A2 Treatment of ocular inflammatory diseases using laquinimod
12/12/2013WO2013184641A1 Fluorescent nitric oxide probes and associated methods
12/12/2013WO2013184621A1 Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
12/12/2013WO2013184591A1 Method of prevention of neurological diseases
12/12/2013WO2013184586A1 Method for treating skin inflammatory diseases
12/12/2013WO2013184564A1 Methods and intermediates for the preparation of fondaparinux
12/12/2013WO2013184202A1 Fbxo3 inhibitors
12/12/2013WO2013184119A1 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
12/12/2013WO2013184023A1 Composition for treating multiple sclerosis (variants)
12/12/2013WO2013184006A1 Ectoparasitic treatment method and composition
12/12/2013WO2013183985A1 Method of treating cognitive impairment and compounds for use therein
12/12/2013WO2013183920A1 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease
12/12/2013WO2013183909A1 Composition for preventing or treating diabetes, containing chestnut tree-derived compound or chestnut tree extract
12/12/2013WO2013183800A1 Crystalline t-butyl 2-[(4r,6s)-6-formyl-2, 2-dimethyl-1,3-dioxane-4-yl]acetate and preparation method therefor
12/12/2013WO2013183784A1 Solid preparation
12/12/2013WO2013183778A1 Composition for mucous membranes
12/12/2013WO2013183718A1 Screening method, protein instability and/or stability inducers, and protein activity assesment
12/12/2013WO2013183678A1 Hair growth composition
12/12/2013WO2013183656A1 Conjugate of g-protein coupled receptor binding ligand and nucleic acid molecule
12/12/2013WO2013183578A1 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR
12/12/2013WO2013183523A1 Method for producing extract from lichen belonging to genus usnea
12/12/2013WO2013183497A1 Dry-coated tablet
12/12/2013WO2013183407A1 Mirtazapine-containing transdermally-absorbable skin-adhesive preparation
12/12/2013WO2013183055A1 Compositions comprising apomorphine and organic acids and uses thereof
12/12/2013WO2013183049A1 Antiviral application of compositions comprising glucan
12/12/2013WO2013182996A1 Mixture for the inhibition of melanin biosynthesis
12/12/2013WO2013182990A1 Oxyclozanide-based veterinary composition for administration to the skin
12/12/2013WO2013182972A1 Benzimidazole-proline derivatives
12/12/2013WO2013182933A1 Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders
12/12/2013WO2013182906A1 Genistein for reducing levels of storage compounds in the treatment and/or prevention of lysosomal storage diseases (lsds)
12/12/2013WO2013182862A1 Synergistic therapies of cannabidiol with hypothermia for neuroprotection
12/12/2013WO2013182851A1 Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
12/12/2013WO2013182850A1 Isobenzofuran- 5 -yl-oxy- (hetero) aryl - imidazolidine - 2, 4 -dione derivatives modulators of kv3 potassium channels for the treatment of cns disorders.
12/12/2013WO2013182759A1 Biosolubilizer
12/12/2013WO2013182711A1 H4 receptor inhibitors for treating tinnitus
12/12/2013WO2013182688A1 A topical gel composition comprising an ingenol derivative and a solvent mixture
12/12/2013WO2013182668A1 Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
12/12/2013WO2013182662A1 Vaccine
12/12/2013WO2013182660A1 Hiv vaccine
12/12/2013WO2013182652A1 Allosteric chaperones and uses thereof
12/12/2013WO2013182638A1 2 -aminothiazinylheteroaryls as bace1 inhibitors for the treatment alzheimer's disease
12/12/2013WO2013182625A1 Pharmaceutical formulation with propargylamine compound
12/12/2013WO2013182580A1 Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
12/12/2013WO2013182578A1 Use of vitamin k to decrease allograft failure and patient mortality after organ transplantation
12/12/2013WO2013182551A1 Saccharide fraction from wheat, isolation process and field of use of the invention
12/12/2013WO2013182546A1 Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase
12/12/2013WO2013182519A1 Combination of lysosomotropic or autophagy modulating agents and a gsk-3 inhibitor for treatment of cancer
12/12/2013WO2013182503A1 Rapamycin 40-o-cyclic hydrocarbon esters, compositions and methods
12/12/2013WO2013182472A1 Pyrazolopyrans having herbicidal and pharmaceutical properties
12/12/2013WO2013182451A1 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
12/12/2013WO2013182423A1 Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
12/12/2013WO2013182411A1 Fluorinated pyridylacetylene derivatives as tracers
12/12/2013WO2013182274A1 Imidazo-oxadiazole and imidazo-thiadiazole derivatives
12/12/2013WO2013182254A1 Pyrrolyl-hydroxamates for use in the prevention and/or treatment of bacterial infections
1 ... 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 ... 7860